CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors' preferences ("Prometheus") in Russia - first results of the survey
The emergence of a new class of drugs - inhibitors of cyclin-dependent kinases 4/6 (CDK4/6) - has changed the paradigm of treatment of patients with luminal HER2 negative metastatic breast cancer. Their effectiveness is confirmed not only by randomized, but also observational studies on a wide heter...
Salvato in:
Autori principali: | , , , , , |
---|---|
Natura: | Libro |
Pubblicazione: |
ABV-press,
2021-01-01T00:00:00Z.
|
Soggetti: | |
Accesso online: | Connect to this object online. |
Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Accesso online
Connect to this object online.3rd Floor Main Library
Collocazione: |
A1234.567 |
---|---|
Copia 1 | Disponibile |